Sino Biopharmaceutical gets China approval for cancer drug trial
Sino Biopharmaceutical announced China's National Medical Products Administration accepted its clinical trial application for TQB3142, a cancer drug candidate.
The independently developed PROTAC molecule degrades the Bcl-xL protein to activate tumor cell death. Studies show significant antitumor activity across multiple tumor models with lower platelet toxicity than similar candidates.
No Bcl-xL inhibitors are currently approved globally, positioning TQB3142 as a potential new cancer treatment option.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
News Alerts
Get instant email alerts when Sino Biopharmaceutical publishes news
Free account required • Unsubscribe anytime